CLINICAL NEWS
meaningful AEs could not be demonstrated,” Dr. Baz
and colleagues wrote. “However, one can anticipate
that cyclophosphamide would result in additional
hematologic toxicities.”
“For patients who are contemplating a pomalidomide-based regimen, a triplet regimen (such as
pomalidomide, cyclophosphamide, and dexamethasone) would be preferred over the doublet &Vv